Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

Status Completed

Clinical Trial Summary

Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. Stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented.

Clinical Trial Description

This study seeks to define the role of gallium nitrate in a specific population of patients who are expected to have received prior therapy. Preliminary clinical studies have suggested substantial evidence of antitumor activity in patients with relapsed or refractory non-Hodgkin's Lymphoma treated with gallium nitrate. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00054808
Study type	Interventional
Source	Genta Incorporated
Contact
Status	Completed
Phase	Phase 2
Start date	June 2002

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03844048` - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial	Phase 3
Completed	`NCT01878890` - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.	Phase 1
Completed	`NCT04152148` - A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients	Phase 1
Recruiting	`NCT05191225` - Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study	Phase 4
Recruiting	`NCT05096234` - 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma	Phase 2
Recruiting	`NCT05623982` - Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03664635` - MB-CART20.1 Lymphoma	Phase 1/Phase 2
Recruiting	`NCT02356159` - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation	Phase 1/Phase 2
Terminated	`NCT01699581` - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant	Phase 2
Completed	`NCT01763398` - Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study	N/A
Completed	`NCT01205503` - Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release	Phase 2
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00969462` - Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma	Phase 4
Completed	`NCT00659425` - CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00608907` - An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)	Phase 1
Terminated	`NCT00475332` - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar	Phase 2
Withdrawn	`NCT00577161` - Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL	Phase 3
Completed	`NCT00533728` - Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00430352` - MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.	Phase 4
Completed	`NCT00581646` - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance	N/A